| Meridian Health Care Providers, Inc. | |
| 10000 North 31st Avenue, Suite D401, Phoenix, Arizona 85051 | |
| (480) 857-0037 | |
| Name | Meridian Health Care Providers, Inc. |
|---|---|
| Location | 10000 North 31st Avenue, Suite D401, Phoenix, Arizona |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 37250 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 85008, 85009, 85013, 85014, 85015, 85016, 85017, 85018, 85019, 85020, 85021, 85022, 85023, 85024, 85027, 85028, 85029, 85032, 85033, 85037, 85041, 85043, 85044, 85048, 85050, 85051, 85053, 85085, 85086, 85087, 85120, 85122, 85123, 85128, 85130, 85131, 85138, 85139, 85140, 85142, 85143, 85194, 85201, 85202, 85203, 85204, 85205, 85206, 85207, 85208, 85209, 85210, 85212, 85215, 85224, 85225, 85226, 85233, 85234, 85248, 85249, 85250, 85251, 85253, 85254, 85255, 85257, 85258, 85259, 85260, 85262, 85266, 85281, 85283, 85284, 85286, 85295, 85298, 85301, 85302, 85304, 85308, 85310, 85323, 85324, 85326, 85331, 85335, 85338, 85339, 85345, 85351, 85353, 85363, 85373, 85374, 85375, 85378, 85379, 85381, 85382, 85383, 85387, 85388, 85392, 85395, 85396 |
| NPI Number | 1982798823 |
| Organization Name | MERIDIAN HEALTH CARE PROVIDERS, INC |
| Address | 10000 N 31st Ave Ste D401, Phoenix, AZ 85051 |
| Phone Number | 480-857-0037 |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.
› Verified 6 days ago
| Quality Rating: |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 100 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 99.8 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 82.9 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 86.7 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 100 | 96.4 |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 84.4 | 79.6 |
| How often patients got better at getting in and out of bed | 89.2 | 81.1 |
| How often patients got better at bathing | 96.5 | 82.3 |
| How often patients’ breathing improved | 87.6 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 98.6 | 75 |
| How often home health patients had to be admitted to the hospital | 14.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 10.9 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 99.8 | 94 |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.
› Verified 6 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.
› Verified 6 days ago
The patient survey data of Meridian Health Care Providers, Inc. is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 80 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 75 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 76 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 80 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 62 | 78 |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.
› Verified 6 days ago
Hospice Of The Valley Home Health Agency Location: 1510 East Flower Street, Phoenix, Arizona 85014 Ratings: NA Phone: (602) 530-6900 | |
Kindred At Home Location: 16620 North 40th Street, Suite D4, Phoenix, Arizona 85032 Ratings: Phone: (602) 992-0709 | |
Bayada Home Health Care, Inc. Location: 706 East Bell Road, Suite 111, Phoenix, Arizona 85022 Ratings: NA Phone: (602) 870-6364 | |
Foundation For Senior Living Home Health Agency Location: 1201 East Thomas Road, Phoenix, Arizona 85014 Ratings: Phone: (602) 285-1800 | |
Amedisys Home Health Care Location: 5045 North 12th Street, Suite 100, Phoenix, Arizona 85014 Ratings: Phone: (602) 200-0835 | |
Md Home Health Location: 7500 Dreamy Draw Drive, Suite 200, Phoenix, Arizona 85020 Ratings: Phone: (602) 266-9971 |